Compare UAN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | PHAR |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2008 | 2020 |
| Metric | UAN | PHAR |
|---|---|---|
| Price | $132.15 | $16.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 62.0K | 6.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 4.72 | N/A |
| Revenue | ★ $606,038,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $28.56 | $3,041.22 |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $80.96 | $8.69 |
| 52 Week High | $139.50 | $21.34 |
| Indicator | UAN | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 45.22 |
| Support Level | $119.03 | $15.96 |
| Resistance Level | $139.42 | $17.28 |
| Average True Range (ATR) | 4.92 | 0.31 |
| MACD | 0.28 | -0.11 |
| Stochastic Oscillator | 61.38 | 8.93 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.